Primer on Tumor Immunology and Cancer Immunotherapy™

Primer on Tumor Immunology and Cancer Immunotherapy™

A Pre-Conference Program; additional registration fee applies 

The understanding of cancer immunobiology has increased dramatically in recent years, leading to the successful development of novel immune-based treatment options to improve cancer patient outcomes. The SITC Primer on Tumor Immunology and Cancer Immunotherapy™ is designed to provide a foundation for understanding core immunology principles as they relate to basic and clinical research in immunotherapy of cancer. New this year, the Primer on Tumor Immunology and Cancer Immunotherapy™ will also touch on emerging therapies and technologies to ensure attendees at all levels stay updated in our expanding field, while also laying a comprehensive foundational base for all SITC 2020 attendees.

Wednesday, Nov. 11, 2020
8 a.m.–5 p.m.

Program Organizers

  • Michael A. Curran, PhD – The University of Texas MD Anderson Cancer Center
  • Yvonne Saenger, MD – Columbia University Irving Medical Center 

Program Schedule 

Program schedule coming soon

Target Audience

The target audience for this annual, one-day educational program includes students, postdoctoral fellows and technicians from academia and industry, as well as physicians and scientists at more senior levels who wish to solidify their understanding of tumor immunology and immunotherapy, pharmacists and registered nurses.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Describe the key principles of tumor immunology and immunotherapy
  • Review current approaches to immunotherapy including immune checkpoint modulation, activation of myeloid cells, modulation of tumor metabolism, T/NK cell adoptive transfer and bispecific antibodies
  • Outline immune monitoring techniques as well as biomarker strategies and their role in trial design and patient selection
  • Enhance scientific exchange with colleagues and collaborators on research and application of cancer immunotherapies to improve outcomes of patients with cancer

Continuing Education

This program will be accredited to offer CME, CNE, CPE and MOC credits.
SITC_Primer_2019.jpg
SITC_2019_Primer_2.jpg